文献速递瓣膜病与结构性心脏病

无症状重度主动脉瓣狭窄:左室健康状态与TAVR时机(EARLY TAVR分析)

Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-09-07

基于EARLY TAVR随机试验901例无症状重度主动脉瓣狭窄患者,评估基线左室健康(整合GLS、LVMi、LAVi)是否改变早期TAVR与临床监测的疗效差异。结果显示无论左室健康是否正常,早期TAVR获益一致;临床监测组2年时左室健康正常者比例更低(35.9% vs 48.1%,P<0.001)。探索性提示左室健康指标指导TAVR时机的价值有限。

要点

  • 基线左室健康(整合或单项指标)不影响早期TAVR相对临床监测的获益。
  • 临床监测组2年时左室健康正常比例显著低于早期TAVR组(35.9% vs 48.1%)。
  • 左室健康指标用于指导无症状重度AS的TAVR时机价值有限(探索性)。

核心结论

  • 无症状重度AS患者中,无论基线左室健康是否正常,早期TAVR相对临床监测的获益一致。
  • 探索性分析提示左室健康指标对指导TAVR时机的价值有限。

研究设计与样本

  • EARLY TAVR试验为多中心随机对照研究,在美国和加拿大75个中心随机901例患者至TAVR(n=455)或临床监测(n=446)。
  • 超声心动图测量由核心实验室完成,整合左室健康定义为绝对GLS≥15%、LVMi<115 g/m2(男)或<95 g/m2(女)、LAVi≤34 mL/m2的复合指标。
  • 整合左室健康为预设次要终点,纵向测量在意向治疗(ITT)和瓣膜植入人群中按方案进行;作为效应修饰分层变量的分析为探索性。

主要发现

  • 随机化时ITT人群中27%整合左室健康正常(LVMi正常64%、LAVi正常42%、GLS正常88%)。
  • 整合左室健康异常及各单项指标异常通常与多个复合终点的事件率更高相关。
  • ITT人群中,临床监测组2年时整合左室健康正常者比例低于早期TAVR组(35.9% vs 48.1%;P<0.001),单项指标亦类似。
  • 临床监测组延迟AVR患者中,除GLS外各指标从随机化至术前有下降趋势(P<0.10)。
  • 基线左室健康未预测转为AVR的时机或就诊严重程度。

关键数值与推荐

  • 整合左室健康定义:绝对GLS≥15%、LVMi<115 g/m2(男)或<95 g/m2(女)、LAVi≤34 mL/m2。
  • 2年整合左室健康正常比例:临床监测组35.9% vs 早期TAVR组48.1%(P<0.001)。

临床怎么用

  • 对无症状重度AS患者,不应仅依据基线左室健康指标延迟TAVR决策。
  • 早期TAVR的获益在不同左室健康状态下一致,支持更早干预策略。

局限性

  • 左室健康作为效应修饰分层变量的分析为探索性,非预设。
  • 临床监测组左室健康恶化与临床事件增加的关联需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with asymptomatic severe aortic stenosis (AS), the EARLY TAVR trial demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS). OBJECTIVES: In this study, the authors sought to evaluate whether baseline left ventricular (LV) health altered the treatment effect of early intervention and to examine longitudinal LV health under different treatment strategies. METHODS: At 75 centers in the United States and Canada, 901 patients underwent randomization to TAVR (n = 455) or CS (n = 446). Echocardiographic measurements were made in a core laboratory. The protocol defined integrated LV health as the composite of absolute LV global longitudinal strain (GLS) ≥15%, LV mass index (LVMi) <115 g/m2 (men) or <95 g/m2 (women), and left atrial volume index (LAVi) ≤34 mL/m2. Integrated LV health was a prespecified secondary endpoint and the protocol outlined longitudinal measurements to be made in the intention-to-treat (ITT) and valve implant populations. As a stratification variable for effect-modification testing, LV health was not prespecified, so those analyses are exploratory. The trial's primary endpoint and 2 secondary composites were examined. RESULTS: At randomization, in the ITT population, 27% had normal integrated LV health (64% normal LVMi, 42% normal LAVi, 88% normal GLS). Abnormal integrated LV health and each component were generally associated with higher event rates across several composite endpoints. Benefit of early TAVR, compared with CS, was consistently observed regardless of whether LV health (evaluated as an integrated measure and as individual components) was normal or not. In the ITT population, the CS group exhibited normal LV health less frequently at 2 years than those treated early according to the integrated LV health measure (35.9% vs 48.1%; P < 0.001) and component measures. Among CS patients undergoing delayed AVR, LV health tended to decline from randomization to preprocedure (P < 0.10 for all measures except GLS), but baseline LV health did not predict timing of conversion to AVR nor severity of presentation. CONCLUSIONS: For patients with asymptomatic severe AS, the benefit of early TAVR, compared with CS, is consistent regardless of baseline LV health according to integrated or individual measures. These exploratory findings suggest limited value for measures of LV health to guide the timing of TAVR in asymptomatic patients. Whether the worsening of LV health associated with CS and delayed aortic valve replacement underlies increased clinical events in that treatment arm requires further study. (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis [EARLY TAVR]; NCT03042104).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lindman BR, Pibarot P, Schwartz A, et al. Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial. J Am Coll Cardiol. 2025. PMID: 41128701. doi:10.1016/j.jacc.2025.08.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。